Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang

기사 요약

Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.